The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Perindoprilat     (2S,3aS,7aS)-1-[(2S)-2- [[(1S)-1...

Synonyms: Perindoprilate, Perindoprilato, Perindorprilat, SureCN564053, AG-J-89020, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of S 9780

 

Psychiatry related information on S 9780

  • In the present study we evaluated the action of perindopril, another ACEI, and two of its metabolites, the di-acide form perindoprilat, which possesses ACE inhibitory properties, and BDM-4, an inactive metabolite, in the learned helplessness paradigm [6].
 

High impact information on S 9780

 

Chemical compound and disease context of S 9780

 

Biological context of S 9780

 

Anatomical context of S 9780

 

Associations of S 9780 with other chemical compounds

 

Gene context of S 9780

 

Analytical, diagnostic and therapeutic context of S 9780

References

  1. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Antony, I., Lerebours, G., Nitenberg, A. Circulation (1996) [Pubmed]
  2. Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. Jaberansari, M.T., Baxter, G.F., Muller, C.A., Latouf, S.E., Röth, E., Opie, L.H., Yellon, D.M. J. Am. Coll. Cardiol. (2001) [Pubmed]
  3. Anti-ischaemic effects of converting enzyme inhibitors: underlying mechanisms and future prospects. Remme, W.J., Bartels, G.L. Eur. Heart J. (1995) [Pubmed]
  4. Vascular effects of intravenous infusion of the angiotensin converting enzyme inhibitor perindoprilat. Benetos, A., Santoni, J.P., Safar, M.E. J. Hypertens. (1990) [Pubmed]
  5. Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition. Bouaziz, H., Joulin, Y., Safar, M., Benetos, A. Br. J. Pharmacol. (1994) [Pubmed]
  6. Involvement of angiotensin-converting enzyme inhibition in reversal of helpless behavior evoked by perindopril in rats. Martin, P., Massol, J., Scalbert, E., Puech, A.J. Eur. J. Pharmacol. (1990) [Pubmed]
  7. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. Nakashima, M., Mombouli, J.V., Taylor, A.A., Vanhoutte, P.M. J. Clin. Invest. (1993) [Pubmed]
  8. ACE inhibition: postsynaptic adrenergic sympatholytic action in men. Lyons, D., Roy, S., O'Byrne, S., Swift, C.G. Circulation (1997) [Pubmed]
  9. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition. Nishiyama, A., Seth, D.M., Navar, L.G. J. Am. Soc. Nephrol. (2002) [Pubmed]
  10. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Yoshiji, H., Kuriyama, S., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., Fukui, H. Clin. Cancer Res. (2001) [Pubmed]
  11. Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Squire, I.B., O'Kane, K.P., Anderson, N., Reid, J.L. Hypertension (2000) [Pubmed]
  12. Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man. MacFadyen, R.J., Lees, K.R., Gemmill, J.D., Hillis, W.S., Reid, J.L. British journal of clinical pharmacology. (1991) [Pubmed]
  13. Prevention of hypoxemia-induced renal dysfunction by perindoprilat in the rabbit. Huet, F., Gouyon, J.B., Guignard, J.P. Life Sci. (1997) [Pubmed]
  14. Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Yamada, S., Muraoka, I., Kato, K., Hiromi, Y., Takasu, R., Seno, H., Kawahara, H., Nabeshima, T. Biol. Pharm. Bull. (2003) [Pubmed]
  15. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Lees, K.R., Green, S.T., Reid, J.L. Clin. Pharmacol. Ther. (1988) [Pubmed]
  16. Acute haemodynamic effects of perindoprilat in essential hypertension at rest and during exercise. Omvik, P., Lund-Johansen, P. J. Hypertens. (1989) [Pubmed]
  17. Role of the renin-angiotensin system on the renal functional reserve in renal transplant recipients. Rondeau, E., Paillard, F., Peraldi, M.N., Violet, I., Tasse, S., Dussaule, J.C., Ardaillou, R., Sraer, J.D. Kidney Int. (1993) [Pubmed]
  18. Prolongation by captopril of action potential duration in the normal and hypertrophied rat ventricle: direct action or inhibition of the local angiotensin converting enzyme? Ribuot, C., Cardinal, R., Gouin, L., Moreau, P., Godin, D., Vermeulen, M., de Champlain, J., Rochette, L., Nadeau, R. Cardiovasc. Res. (1994) [Pubmed]
  19. The role of bradykinin in the antifibrotic actions of perindoprilat on human mesangial cells. Pawluczyk, I.Z., Patel, S.R., Harris, K.P. Kidney Int. (2004) [Pubmed]
  20. Effects of perindoprilat on endothelium-dependent relaxations and contractions in isolated blood vessels. Kerth, P.A., Vanhoutte, P.M. Am. J. Hypertens. (1991) [Pubmed]
  21. Systemic and regional hemodynamic effects of perindopril in experimental heart failure. Medvedev, O.S., Gorodetskaya, E.A. Am. Heart J. (1993) [Pubmed]
  22. Interaction of perindoprilat with human red blood cells. Piasecka, A., Marciniak, K., Koter, M., Krajewska, E., Leyko, W., Bryszewska, M. Scand. J. Clin. Lab. Invest. (1999) [Pubmed]
  23. Endogenous angiotensin II enhances phenylephrine-induced tone in hypertensive rats. Qiu, H.Y., Henrion, D., Levy, B.I. Hypertension (1994) [Pubmed]
  24. Early captopril treatment inhibits DNA synthesis in endothelial cells and normalization of maximal coronary flow in infarcted rat hearts. Nelissen-Vrancken, H.J., Kuizinga, M.C., Daemen, M.J., Smits, J.F. Cardiovasc. Res. (1998) [Pubmed]
  25. Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells. Kishi, Y., Ohta, S., Kasuya, N., Sakita, S.Y., Ashikaga, T., Isobe, M. J. Hypertens. (2003) [Pubmed]
  26. Presence of angiotensin converting enzyme in the adventitia of large blood vessels. Rogerson, F.M., Chai, S.Y., Schlawe, I., Murray, W.K., Marley, P.D., Mendelsohn, F.A. J. Hypertens. (1992) [Pubmed]
  27. Acute effects of angiotensin-converting enzyme inhibition on coronary vasomotion in hypertensive patients. Nitenberg, A., Antony, I. Eur. Heart J. (1998) [Pubmed]
  28. Perindopril. A review of its pharmacokinetics and clinical pharmacology. Macfadyen, R.J., Lees, K.R., Reid, J.L. Drugs (1990) [Pubmed]
 
WikiGenes - Universities